Compare IDEXX Laboratories, Inc. (IDXX) vs NetFlix Inc (NFLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs NetFlix Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while NetFlix Inc trades at $70.3 (market cap $298.01B). The key difference: NetFlix Inc is far larger — about 7.4× IDEXX Laboratories, Inc.'s market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 45,805,108). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and NetFlix Inc for 125 Days on average.
| IDXX | NFLX | |
|---|---|---|
Market Cap | $40.43B | $298.01B |
Volume | 692,164 | 45,805,108 |
Sector | Health | Media |
52-Week High | $766.68 | $124.13 |
52-Week Low | $504.70 | $67.06 |
Typical Hold Time | 46 Days | 125 Days |
Enterprise Value | $41.32B | $303.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Netflix trades at $69.70, up 1.47% today, with strong fundamentals including 28.2% net margin and 49.5% ROE. The stock shows bearish technical signals despite beating earnings expectations for three consecutive quarters. Recent news highlights Netflix's live sports strategy and content investments, while analyst consensus remains bullish with a $89.78 price target representing 29% upside potential.
Netflix presents a compelling growth story with expanding profitability and strategic content investments, though technical weakness and competitive pressures warrant caution. The company's strong cash flow generation and institutional interest support long-term upside, but investors should monitor execution risks in the evolving streaming landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
